JPRN-jRCT2031220323进行中（未招募）Unknown
Special drug use observational study with Beovu kit for intravitreal injection (DME, CRTH258B1401)
Sugimoto Toshiya0 个研究点目标入组 200 人开始时间: 2022年9月8日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients must provide written consent to cooperate in this study before the start of treatment with Beovu
- •2. Patients using Beovu for the first time for the following indication
- •- Indication: diabetic macular edema
排除标准
- •Patients with a history of treatment with a drug containing the same ingredient (brolucizumab) as Beovu
研究者
相似试验
已完成
不适用
Special Drug Use Observational Study With Beovu Kit for Intravitreal InjectionDiabetic Macular EdemaNCT05526729Novartis Pharmaceuticals222
进行中（未招募）
不适用
Protocol Number; CAIN457L1401JPRN-jRCT2031210589Toshiya Sugimoto35
招募中
不适用
Therapeutic drug monitoring study for avoiding severe neutropenia of amrubicin therapy based on the exposure-response relationship with pharmacokinetic/pharmacodynamic parameters.Small cell lung cancerJPRN-UMIN000045953Saitama Medical University44
已完成
4 期
Prospective observational study on the key drug selection in advanced/recurrent EGFR mutation-positive non-small-cell lung cancerJPRN-UMIN000028989Osaka International Cancer Institute524
已完成
Unknown
Special Drug Use-Results Survey of OPDIVO (classical Hodgkin's lymphoma)classical Hodgkin's lymphomaJPRN-jRCT1080224013ONO PHARMACEUTICAL CO.,LTD.250